Myeloproliferative Neoplasms News

Certain patients with hematologic malignancies and COVID-19 appeared at higher risk for severe infection and death, according to an analysis of data from an international registry presented at the virtual ASH Annual Meeting and Exposition.

Older patients with myelodysplastic syndrome who underwent donor-matched allogeneic hematopoietic stem cell transplant had significantly improved survival outcomes compared with those who did not have a matched donor, study results showed.

The addition of tranexamic acid prophylaxis to platelet transfusion did not reduce bleeding among patients with blood cancers and severe thrombocytopenia, according to study results presented at the virtual ASH Annual Meeting and Exposition.

Treatment with imetelstat led to durable transfusion independence for certain heavily transfused patients with lower-risk myelodysplastic syndrome, according to study results published in Journal of Clinical Oncology.

ASH announced the election of four new members to its executive committee.

Four Cleveland Clinic oncology staff members have been appointed to new roles at Taussig Cancer Institute.

Anthony S. Fauci, MD will be a keynote speaker during a special session at this year’s virtual ASH Annual Meeting and Exposition.

A phase 3 trial of omidubicel has shown the graft modality superior to standard umbilical cord blood for bone marrow transplantation in patients with hematologic malignancies, according to topline data released by the agent’s manufacturer.

Clinical trials have played a key role in the development of targeted treatments that have improved outcomes for patients with cancer.

SF3B1 mutations occurred more frequently in de novo myelodysplastic syndromes than therapy-related myelodysplastic syndrome, according to results of a phase 2 study presented at Society of Hematologic Oncology Annual Meeting.